<DOC>
	<DOC>NCT00167999</DOC>
	<brief_summary>To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units</brief_summary>
	<brief_title>Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Klebsiella Infections</mesh_term>
	<mesh_term>Escherichia coli Infections</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
	<criteria>Eligible patients of either sex, 15 years of age or older Patients who are admitted to the department of hematology and oncology Provide written informed consent Patients who have hypersensitivity to Î²lactam antibiotics Female who are pregnant or breastfeeding Any underlying conditions or noninfectious diseases that will be ultimately fatal within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Bacterial Infections</keyword>
</DOC>